Biogen's purchase of MS drug ends rocky partnership with Elan

BOSTON (Reuters) - Biogen Idec Inc's agreement to buy Elan Corp Plc's interest in the multiple sclerosis drug Tysabri gives Biogen full control of a product that is poised for further growth and ends a long partnership that has often been contentious.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news